A challenging economic environment is constricting biotech deal flow. But for well-capitalized Lantheus, these tough times ...

"We are excited to be partnering with Lantheus to bring Granzyme B PET imaging to the forefront. This strategic collaboration creates a clear path to commercialization with an ideal partner in the ...

Through the transaction, Lantheus has acquired OCTEVY™, a registrational-stage PET diagnostic imaging agent targeting neuroendocrine tumors, which complements Lantheus’ therapeutic candidate ...

MK-6420. Lantheus is also attempting to expand its radiopharmaceutical diagnostic offerings, the most notable of which is MK-6420, a second-generation F18-labeled PET imaging agent that targets ...

Pictet Asset Management Holding SA boosted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 12.1% in the fourth quarter, according to the company in its most recent Form 13F ...

"We are excited to be partnering with Lantheus to bring Granzyme B PET imaging to the forefront. This strategic collaboration creates a clear path to commercialization with an ideal partner in the ...

The acquisition was first announced on January 28, 2025. Through the transaction, Lantheus has acquired OCTEVY™, a registrational-stage PET diagnostic imaging agent targeting neuroendocrine tumors, ...